|
 |
Coagulation factor VIIaThis page contains recent news articles, when available, and an overview of Coagulation factor VIIa but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Coagulation factor VIIa (when available) Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting. For treatment of hemorrhagic complications in hemophilia A and B Mechanism Of Action: NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin. News Articles on Coagulation factor VIIa GTC Biotherapeutics Receives NASDAQ Notice of Non-Compliance - Jul 18, 2008 These proteins include recombinant forms of human coagulation factor VIIa, factor VIII, factor IX, and alpha-1 antitrypsin. GTC also has a monoclonal MarketWatch Pharmaceutical Study: Less Hemorrhaging After Stroke, But Not ... - Jun 16, 2008 16, 2008) — An international study published in May 2008 in the New England Journal of Medicine has shown that the coagulation factor VIIa can limit the Science Daily (press release) Novo Nordisk Halts Trial of Traumatic Bleeding Drug for Futility - Jun 18, 2008 NovoSeven (coagulation factor VIIa [recombinant]) is a hemophilia drug that was undergoing a safety and efficacy study in severely injured blunt trauma FDA news (subscription), FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor ... - May 13, 2008 By Novo Nordisk Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved NovoSeven(R) RT (Coagulation Factor VIIa SunHerald.com, FDA OKs new coagulation formulation - May 12, 2008 NovoSeven RT -- the new formulation of NovoSeven Coagulation Factor VIIa (Recombinant) -- contains sucrose and L-Methionine, which allows storage at room United Press International Catalyst Biosciences Selects Drug Development Candidate in Factor ... - May 6, 2008 ...second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. Earthtimes (press release), FDA Approvals: Amitiza, Strattera, NovoSeven RT - May 15, 2008 Describe the potential benefits of a new formulation for recombinant coagulation factor VIIa intravenous injection. Disclosure: Yael Waknine has disclosed Medscape (subscription) NovoSeven RT approved to control surgical bleeding - May 12, 2008 The FDA has approved Novo Nordisk's NovoSeven RT (recombinant human coagulation factor VIIa), another formulation of NovoSeven, that can be stored at room Prescribing Reference, GTC Biotherapeutics Reports Fourth Quarter and Year End 2007 ... - Mar 6, 2008 We developed production animals for the recombinant human coagulation factor VIIa program with LFB Biotechnologies. We licensed exclusive rights to North Business Wire (press release), GTC Biotherapeutics to Webcast Corporate Presentation at the 10th ... - 06 Feb 2008 These proteins include recombinant forms of human coagulation factor VIIa, factor VIII, factor IX, and alpha-1 antitrypsin. GTC also has a monoclonal WELT ONLINE, LFB Biotechnologies to Collaborate with GTC Biotherapeutics on ... - Jan 10, 2008 These proteins include recombinant forms of human coagulation factor VIIa, factor VIII, alpha-1 antitrypsin and ATryn(R), GTC's recombinant form of human PharmaLive.com (press release), Blunt Trauma Patients Who Receive Recombinant Activated Factor ... - Jul 11, 2007 DG News...is significantly reduced in trauma and surgical patients with massive haemorrhage who receive recombinant activated coagulation Factor VIIa (rFVIIa, Novo Nordisk starts Phase I trial of long-acting version of NovoSeven - Jun 15, 2007 Forbes,...initiated a phase 1 clinical trial of GlycoPEGylated factor VIIa, a long-acting version of the group's NovoSeven Coagulation Factor VIIa (recombinant). Novo Nordisk, Neose Technologies Initiate Phase I Trial Of Long ... - Jun 15, 2007 Trading Markets,...said that Novo Nordisk commenced a Phase I clinical trial of GlycoPEGylated Factor VIIa, a long-acting version of NovoSeven Coagulation Factor VIIa. Minnesota Thermal Science Awarded Special Forces Contract for ... - May 1, 2007 Emediawire (press release),...its recently designed specialized thermal container that will be used by US Special Forces to transport emergency dosages of "Coagulation Factor VIIa. Food and Drug Administration Public Hearing of the Conduct of ... - Mar 30, 2007 AEM (subscription)Five years ago, we began using recombinant human coagulation factor VIIa as a rescue therapy for patients with intractable hemorrhage, and I started to work Prophylactic Factor VIIa Improves Quality of Life for Hemophiliacs ... - Dec 11, 2006 DG NewsORLANDO, FL -- December 11, 2006 -- Once daily administration of recombinant human coagulation factor VIIa as secondary prophylaxis against joint bleeding Decreased Bleeding Frequency With Secondary Prophylactic Use Of ... - Dec 13, 2006 Medical News Today (press release),Data presented at the 48th Annual Meeting of the American Society of Hematology (ASH) from a study testing the use of NovoSeven® Coagulation Factor VIIa FDA Approves Supplemental Use of NovoSeven(R) Coagulation Factor ... Oct 17, 2006 17, 2006 -- The United States Food and Drug Administration (FDA) has approved a new indication for NovoSeven(R) Coagulation Factor VIIa (Recombinant), making ... -DG News NovoSeven(R) Becomes First and Only Recombinant Therapy for ... Oct 17, 2006 ...~ FDA Approves Supplemental Use of NovoSeven(R) Coagulation Factor VIIa (Recombinant) for Treatment of Acquired Hemophilia ~ PRINCETON, NJ, Oct. ... -PR Newswire (press release), Market Report -- In Play (NVO) Oct 17, 2006 Novo-Nordisk A/S announces the FDA has approved a new indication for NovoSeven Coagulation Factor VIIa Co announces the FDA has approved a new indication for ... -MSN Money Market Report -- In Play (NVO) Oct 27, 2006 ...by 16% in the first nine months of 2006: sales of insulin analogs increased by 52%; sales of NovoSeven Coagulation Factor VIIa (Recombinant) increased by 13 ... -MSN Money FDA Approves Nuvelo's (NUVO) Recombinant Therapy to Treat Rare ... Oct 17, 2006 Nuvelo Inc. (NUVO) said the FDA has approved a new indication for NovoSeven Coagulation Factor VIIa (Recombinant), making it the first and only recombinant ... -StreetInsider.com (subscription), NovoSeven(R) Becomes First and Only Recombinant Therapy for ... Oct 17, 2006 PRNewswire/ -- The United States Food and Drug Administration (FDA) has approved a new indication for NovoSeven® Coagulation Factor VIIa (Recombinant), making ... -Yahoo! News (press release) Novo Nordisk Announces Financial Statement for the First Nine ... Oct 27, 2006 ...by 16% in the first nine months of 2006 - Sales of insulin analogs increased by 52% - Sales of NovoSeven(R) Coagulation Factor VIIa (Recombinant) increased by ... -MSN Money NovoSeven Approved for Additional Indication Oct 20, 2006 The FDA has approved Novo Nordisk’s SNDA for NovoSeven (coagulation factor VIIa [recombinant]) for the treatment of acquired hemophilia. ... -Facts and Comparisons, Novo Nordisk Reports 20% Increase In First Half Reported Sales ... Aug 2, 2006 ...last year. Specifically, sales of insulin analogs increased by 59% and NovoSeven Coagulation Factor VIIa improved by 19%. Sales ... -Trading Markets Novo Nordisk Increased Sales by 20% in the First Six Months Aug 2, 2006 ...by 20% in the first six months of 2006 -- Sales of insulin analogs increased by 59% -- Sales of NovoSeven(R) Coagulation Factor VIIa (Recombinant) increased by ... -Finanzen.net Recombinant Factor VIIa and Thromboembolic Events Jul 4, 2006 To the Editor: Dr O’Connell and colleagues 1 reviewed thromboembolic complications of recombinant human coagulation factor VIIa (rFVIIa) as reported to the ... -Journal of American Medical Association (subscription) Novo Nordisk withdraws NovoSeven marketing extension application Apr 7, 2006 NovoSeven (Human recombinant coagulation Factor VIIa (rFVIIa)) was first authorized in the European Union in February 1996 and is currently indicated for the ... - Pharmaceutical Business Review Novo Nordisk Withdraw Their Application To Extend The Marketing ... Apr 6, 2006 ...withdraw the application for an extension of the marketing authorisation for the medicinal product NovoSeven (Human recombinant coagulation Factor VIIa (rFVIIa ... - Medical News Today Brand Names/Synonyms: Coagulation factor VIIa is also known by the following brand names and/or synonymsCoagulation factor VII precursor;Serum prothrombin conversion accelerator;SPCA;Proconvertin;Eptacog alfa; NovoSeven (Novo Nordisk) Drug Category: Coagulation factor VIIa is categorized under the following by the FDA: Coagulants; Thrombotic Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Human coagulation factor VIIa : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |